Biocon demonstrated strategic agility by entering new business areas early and adapting to changes in the pharmaceutical industry. It moved into biologics as patients and investigators for US trials were limited in India. When blockbuster drugs lost patent protection and India updated its IP rules, Biocon responded by focusing on generics. It showed resource fluidity by creating new businesses, reorganizing its workforce, and continuously investing in R&D.